BioCentury
ARTICLE | Clinical News

Bavituximab: Updated Phase IIb data

February 25, 2013 8:00 AM UTC

Updated data based on the completion of an earlier review of discrepancies from a double-blind, international Phase IIb trial in 121 patients with second-line locally advanced or metastatic non-squamous NSCLC showed that 3 mg/kg bavituximab plus docetaxel led to a median OS, a secondary endpoint, of 11.7 months vs. 7.3 months for the control arm (p=0.217). In the updated analysis, the control arm consisted of the combined placebo and 1 mg/kg bavituximab arms. Peregrine said an end-of-Phase II meeting with FDA is expected in mid-2013 with a Phase III trial evaluating 3 mg/kg bavituximab plus docetaxel as second-line treatment of NSCLC slated to start by year end. ...